Research will be carried out by consortium of African and European researchers
Public and private funders have awarded €44 million (US$49m) to a consortium that will evaluate new medicines to treat drug-resistant malaria on the continent.
The funding comes from the European and Developing Countries Clinical Trials Partnership, pharmaceutical company Novartis, and the Medicines for Malaria Venture.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.